Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-godkendelsesundersøgelse

6. november 2026 opdateret af: Microvention-Terumo, Inc.

The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

154

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Florida
      • Hollywood, Florida, Forenede Stater, 33021
        • Memorial Healthcare Systems
      • Orlando, Florida, Forenede Stater, 32806
        • Orlando Health
    • Hawaii
      • Honolulu, Hawaii, Forenede Stater, 96813
        • Queen's Medical Center
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • University of Iowa
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • University of Kansas
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40241
        • Norton Healthcare
      • Louisville, Kentucky, Forenede Stater, 40207
        • Baptist Healthcare System
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Ochsner Health
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • The Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Brigham Incorporated
      • Worcester, Massachusetts, Forenede Stater, 01655
        • UMass Memorial Health
    • New York
      • Albany, New York, Forenede Stater, 12208
        • Albany Medical Center
      • Buffalo, New York, Forenede Stater, 14203
        • University at Buffalo
      • Manhasset, New York, Forenede Stater, 11030
        • Northwell Health
      • New York, New York, Forenede Stater, 10029
        • Mount Sinai
      • Stony Brook, New York, Forenede Stater, 11794
        • Stony Brook University
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Ohio State University
      • Toledo, Ohio, Forenede Stater, 43606
        • ProMedica Toledo Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • University of Oklahoma Health Sciences Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • University of Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Thomas Jefferson University
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Houston Methodist Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

22 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Subjects for this study must meet ALL the following criteria:

  1. Subject has single target aneurysm in the internal carotid artery from petrous segment to the terminus of the internal carotid artery.
  2. The parent artery diameter must be 2.0 - 5.0 mm distal and/or proximal to the target intracranial aneurysm.
  3. Negative pregnancy test (serum or urine) in a female subject who has had menses in the last 18 months.
  4. Subject commits to return to the investigational site for the 30- day, 6-month, 12-month, 2-year, 3-year, and 5-year follow-up evaluations.
  5. The subject or his/her authorized representative must sign the IRB-approved written informed consent form prior to the start of any study procedures.
  6. The subject has a modified Rankin Scale (mRS) ≤ 2.
  7. The subject has a wide-necked ( ≥4mm or dome-to-neck ratio <2) saccular or fusiform aneurysm.

Exclusion Criteria:

Subjects shall be excluded from the study if ANY of the following conditions exist:

  1. Subject who suffers from a subarachnoid hemorrhage in the last 60 days.
  2. Subject who suffers from intracranial hemorrhage in the last 30 days.
  3. Subject who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region.
  4. Subject with symptomatic extracranial or intracranial stenosis of the parent artery (>50%) proximal to the target aneurysm.
  5. Subject with an irreversible bleeding disorder, a platelet count < 100 x 103 cells/mm3 or known platelet dysfunction or a contraindication to or inability to tolerate anticoagulants/antiplatelet agents or thrombolytic drugs.
  6. Subject with history of major bleeding disorder (based on coagulation profile and platelet count) and/or subject presents with signs of active bleeding.
  7. Subject with known hypersensitivity to any component of the treatment device that cannot be medically controlled.
  8. Subject with documented contrast allergy, or other condition that prohibits imaging.
  9. Evidence of active bacterial infection at the time of treatment.
  10. Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%.
  11. Subject with a pre-existing stent in place at the target aneurysm.
  12. Subject who is unable to complete the required follow-ups.
  13. Subject who is pregnant, breastfeeding, or of childbearing potential and unwilling to prevent pregnancy during their participation in the study.
  14. Subject has a serious or life-threatening comorbidity that could confound study results and/or prevent completion of 5-year followup.
  15. Subject is enrolled in another device or drug study in which participation could confound study results.
  16. Subject has absent femoral pulses or other condition preventing femoral access, or is planned to be treated using a radial access approach.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Flow Re-Direction Endoluminal Device X

FRED™ X™ device

The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.

Andre navne:
  • Flow Re-Direction Endoluminal Device X

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Primary Safety Endpoint Part 1: Proportion of subjects that experience either Death or major stroke within 30 days post-procedure.
Tidsramme: 30-days

Major stroke is defined as a new neurological event that persists for >24 hours and results in a ≥4-point increase in the NIHSS score compared to baseline or compared to any subsequent lower score.

30-days
Primary Safety Endpoint Part 2: Proportion of subjects that experience neurological death or major ipsilateral stroke within 12 months post-procedure.
Tidsramme: 12 months

A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurological death is defined as a death which has been adjudicated by an independent clinical events committee to have directly resulted from a neurologic cause.

12 months
Primary Effectiveness Endpoint: The percent of subjects with (1) complete (100%) occlusion of the target aneurysm and ≤50% stenosis of the parent artery at the target IA, and (2) in whom an alternative treatment of the target IA had not been performed.
Tidsramme: 12 months

(1) Complete (100%) occlusion of the target aneurysm is assessed utilizing the Raymond-Roy Scale (Raymond Roy Class 1) and ≤50% stenosis of the parent artery at the target IA), and in whom an alternative treatment of the target IA had not been performed. The study will utilize independent Core Laboratory to adjudicate all angiographic outcomes, including aneurysm occlusion status and parent artery stenosis. (2) Alternative treatment is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of in-stent stenosis.

12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. september 2022

Primær færdiggørelse (Anslået)

1. april 2027

Studieafslutning (Anslået)

1. maj 2030

Datoer for studieregistrering

Først indsendt

4. juni 2022

Først indsendt, der opfyldte QC-kriterier

4. juni 2022

Først opslået (Faktiske)

8. juni 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CL11023

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .